Open AccessSojini izoflavoni kot pristop prve izbire pri zdravljenju vazomotoričnih težav v menopavzi
Author(s) -
Mathias Schmidt,
Karin Arjomand-Wölkart,
Martin Birkhäuser,
Andrea R. Genazzani,
Doris Gruber,
J Huber,
H. Kölbl,
Samo Kreft,
Sepp Leodolter,
Doris Linsberger,
M. Metka,
Tommaso Simoncini,
Lucija Vrabič-Dežman
Publication year - 2016
Publication title -
zdravniški vestnik
Language(s) - English
Resource type - Journals
eISSN - 1581-0224
pISSN - 1318-0347
DOI - 10.6016/zdravvestn.1668
Subject(s) - isoflavones , medicine , menopause , clinical trial , adverse effect , physiology , anastrozole , incidence (geometry) , breast cancer , endocrinology , tamoxifen , cancer , physics , optics
The link between higher uptake of isoflavones and a reduced frequency of menopause-related hot flushes were first described in 1992 based on a lower incidence of hot flushes in countries with high dietary soy intake1. Since then, a number of clinical trials with different sources of isoflavones, including soy and red clover, have been performed, and in almost all studies with an appropriate design the outcome was in favour of isoflavone supplementation2. A detailed risk assessment3 revealed that a number of data in humans do not confirm the alleged adverse effect resulting from possible interaction between isoflavones and the hormone-sensitive tissues of the mammary glands, uterus and thyroid. Safety was demonstrated by long-term intake of 150 mg of isoflavones per day, which lasted at least three years. It was also found that a high intake of isoflavones prevented the occurrence of breast cancer4-7. Clinical findings indicate potential benefits of exposure to isoflavones during breast cancer treatment with tamoxifen or anastrozole.